Patent · US Active

Heterocyclic derived metalloprotease inhibitors

US7803793B2 · kind B2 · utility

4Cited by

0References

32Claims

0Family size

Assignee

Janssen Pharmaceuticals, Inc. · BE

Inventors

Yue-Mei Zhang · Wellesley, US
Bangping Xiang · Bound Brook, US
Shyh-Ming Yang · Doylestown, US
Kenneth Rhodes · Belmont, US
Robert Scannevin · Hopkinton, US
Paul F. Jackson · Bel Air, US
Davraj Chakravarty · Fryeburg, US
Xiaodong Fan · Radnor, US
Lawrence Wilson · Mason, US
Prabha Saba Karnachi · Fryeburg, US

Key dates

Filing date	Sep 21, 2007
Grant date	Sep 28, 2010
Priority date	—
Expiry date	Aug 3, 2028

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D409/12
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention provides novel heterocyclic derived matrix metalloprotease inhibitors of the formula:and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing matrix metalloproteases. This invention also provides therapeutic and prophylactic methods using the instant pharmaceutical compositions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.